Company: FTII
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001641172-25-025250
Chunk: 48

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 48
---
,537,744 outstanding under the Extension Loans from the Sponsor. As of June 30, 2025, there was $3,537,744
outstanding under the Extension Loans from the Sponsor.

5

Business
Combination; Merger Agreement with Longevity Biomedical Inc.

On
September 16, 2024, the Company, entered into a Merger Agreement”, by and among the Company, Longevity, LBI Merger Sub, Inc., and
Bradford A. Zakes, solely in the capacity as seller representative.

Pursuant
to the Merger Agreement, the parties thereto will enter into the Transactions, pursuant to which, among other things, immediately following
the consummation of the acquisitions by Longevity of each of Cerevast Medical, Inc. and Aegeria Soft Tissue LLC, Longevity will merge
with and into LBI Merger Sub, with Longevity as the surviving entity and becoming a wholly-owned subsidiary of the Company. At the closing
of the Transactions (the “Closing”), the Company is expected to change its name to “Longevity Biomedical, Inc.”
and the Company’s common stock is expected to list on the NASDAQ Capital Market under the ticker symbol “LBIO.”

The
consummation of the proposed Longevity Business Combination is subject to certain conditions as further described in the Merger Agreement.

In
connection with the execution of the Merger Agreement, the sole stockholder of Longevity (the “Voting Stockholder”) has entered
into a Voting and Support Agreement (the “Longevity Support Agreement”) with the Company and Longevity, pursuant to which
the Voting Stockholder has agreed to, among other things, (i) vote in favor of the Merger Agreement and the transactions contemplated
thereby and (ii) be bound by certain other covenants and agreements related to the Transactions. The Voting Stockholder holds sufficient
shares of Longevity to cause the approval of the Transactions on behalf of Longevity.

In
connection with the execution of the Merger Agreement, the Company, Longevity, the Sponsor have entered into a Voting and Support Agreement
(the “Sponsor Support Agreement”). The Sponsor Support Agreement provides that the Sponsor agrees (i) to vote in favor of
the proposed transactions contemplated by the Merger Agreement, (ii) to appear at the purchaser special meeting for purposes of constituting
a quorum, (iii) to vote against any proposals that would materially impede the proposed transactions